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To the Editor: We would like to thank Dr Elsner and colleagues for the interest they have shown in our work [1, 2] . To comment properly on the data, however, we would have to see more details of their study regarding the longevity of blood glucose reduction and the results of glucose tolerance tests. We think that without this additional information it is difficult to comment on the efficacy of their procedure and the claims that transdifferentiation is not required. We think it is logical to predict normalisation of glucose levels after hepatic expression of insulin, and this has been shown to a greater or lesser extent in numerous studies. In Elsner's study it is not clear whether this reduction in blood glucose levels can be sustained without induction of hypoglycaemia and whether glucose secretion was tightly regulated. Indeed the blood glucose level of the animals was not reduced to anywhere near normal levels. Whilst insulin staining was seen, there are no data to show whether or not this was in secretory granules, as was seen in our study. While there has been some indication that the type of furin-cleavable insulin used in this study may cause mutations, the transdifferentiation seen in our study is not a sole result of this, if at all. In previous preliminary work we have delivered this insulin in different vectors and by different methods, and seen no transdifferentiation or such tightly controlled blood glucose homeostasis as seen in the study published in Diabetologia. We wait with interest to see Dr. Elsner's data once they are published.
